CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis
Authors
I. Cherrez-Ojeda Vanegas, E. Cherrez, A. Felix, M. Weller, K. Magerl, M. Maurer, R.R. Mata, V.L. Kasperska-Zajac, A. Sikora, A. Fomina, D. Kovalkova, E. Godse, K. Rao, N.D. Khoshkhui, M. Rastgoo, S. Criado, R.F.J. Abuzakouk, M. Grandon, D. Van Doorn, M.B.A. Rodrigues Valle, S.O. De Souza Lima, E.M. Thomsen, S.F. Ramón, G.D. Matos Benavides, E.E. Bauer, A. Giménez-Arnau, A.M. Kocatürk, E. Guillet, C. Larco, J.I. Zhao, Z.-T. Makris, M. Ritchie, C. Xepapadaki, P. Ensina, L.F. Cherrez, S. Maurer, M.
Publication date
1 January 2021
Publisher
Abstract
Background: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. Results: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research. © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:2999689
Last time updated on 10/02/2023